REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2012 by University of Kentucky.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Kenneth Ain, University of Kentucky
ClinicalTrials.gov Identifier:
NCT00287287
First received: February 3, 2006
Last updated: September 17, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)